HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This is a mono-center open-label proof-of-concept pharmacologic study to explore the efficacy
and safety of vorinostat in advanced BRAF mutated melanoma, which became resistant for
BRAF-inhibitors or the combination of BRAF- and MEK-inhibitors.